Dr. Aronow's research focuses on understanding the role of biomarkers in assessing response to therapy in uveal melanoma, the most common primary intraocular malignancy in adults. Specifically, she is investigating the role of plasma tumor DNA (ptDNA) in monitoring disease activity following treatment of these tumors. Ultimately, the goal is to develop highly targeted therapies for patients with uveal melanoma. As newer therapies become available, ptDNA has the potential to serve as a biomarker for assessing treatment efficacy. Macro-metastatic disease detected with CT or MRI imaging may take five or more years to develop. In contrast, ptDNA has the potential to serve as a marker of disease activity, thus allowing for detection of micro-metastases at an earlier time point and intervention with promising adjuvant therapies.
For a full publication list, please see her CV.
Singh AD, Medina CA, Singh N, Aronow ME, Biscotti CV, Triozzi PL. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol. 2016 Apr;100(4):456-62.
Campochiaro PA, Hafiz G, Mir TA, Scott AW, Zimmer-Galler I, Shah SM, Wenick AS, Brady CJ, Han I, He L, Channa R, Poon D, Meyerle C, Aronow ME, Sodhi A, Handa JT, Kherani S, Han Y, Sophie R, Wang G, Qian J. Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with ozurdex trial. Am J Ophthalmol. 2016;168:13-23.
Aronow ME, Murray TG, Shields CL. Key Opinion Leaders: Diagnosing and managing choroidal nevi and melanoma. Retina Times. 2015;33(5):32-41.
Aronow ME, Shen D, Hochman J, Chan CC. Intraocular lymphoma models. Ocular Oncol Pathol. 2015;1:214-22.
Aronow ME. Ocular adnexal lymphoma: evidence-based treatment approach. Int Ophthalmol Clin. 2015;55(1):97-109.
View a complete list of publications on pubmed.gov>>